Get 40% Off
🔎 See NVDA's full ProTips for an instant risks or rewardsClaim 40% OFF

Heron Therapeuti (HRTX)

NASDAQ
Currency in USD
Disclaimer
2.88
+0.01(+0.35%)
Closed
After Hours
2.80-0.08(-2.78%)
Earnings results expected in 6 days
Day's Range
2.802.96
52 wk Range
0.502.99
Prev. Close
2.87
Open
2.86
Day's Range
2.8-2.96
52 wk Range
0.5-2.99
Volume
1,958,509
Average Vol. (3m)
3,106,472
1-Year Change
6.67%
Shares Outstanding
150,072,640
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
6.67
Upside +131.60%

People Also Watch

787.57
SMCI
-1.96%
3.580
MREO
-3.50%
401.49
MOH
-0.06%
31.22
PLAB
-6.58%
8.550
ARDX
-5.42%
How do you feel today about HRTX?
Vote to see community's results!
or

Heron Therapeuti Company Profile

Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF, HTX-019, and HTX-034. HTX- ZYNRELEF is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting in adults. HTX-034 is a product candidate for postoperative pain management.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.